SoleStim Neuromodulation System, a home-use device for the treatment of dysmenorrhea

Abstract
Pain and accompanying symptoms of primary dysmenorrhea, a condition defined by cramping-associated pain
during menstruation without identifiable pelvic pathology, are a true disturbance to daily activities and quality of
life. High prevalence of dysmenorrhea translates to over 855 million people suffering from this condition
worldwide. Severe symptoms of dysmenorrhea force up to 33% to miss school or work, resulting in 600 million
hours missed annually and an annual economic burden of over $2 billion in the U.S. Non-steroidal anti-
inflammatory drugs (NSAIDs) and hormonal contraception (HC) are the first-line options for treating
dysmenorrhea, but with 20-25% of people not responding to NSAIDs and many finding the side effects of NSAID
and HC use to be unacceptable, the overall effectiveness of these therapies is limited. Thus, there remains an
urgent unmet medical need worldwide to develop a safe, effective, and accessible therapy for dysmenorrhea.
Recent clinical studies have shown that acupuncture-based nerve stimulation of a specific peripheral nerve can
be effective for treating dysmenorrhea symptoms. While promising for reducing pain and distress, acupuncture’s
low acceptability to patients and the need for scheduled care at the clinic prevent its potential widespread use
for dysmenorrhea treatment. To build on this work and address the need for a comprehensive therapy for
dysmenorrhea, TheraNova has developed the SoleStim Neuromodulation System, a portable, non-invasive
,Plantar Neuromodulation (PNM) device for non-invasive stimulation of peripheral nerves. The SoleStim
Neuromodulation System consists of standard, inexpensive gel electrodes and a small, battery-powered signal
generator. The goal of this proposal is to conduct a pilot clinical study to evaluate the potential of SoleStim as a
treatment for dysmenorrhea. We will conduct a 16-week, sham-controlled study in 33 participants with primary
dysmenorrhea. Treatment effectiveness will be evaluated via participant-reported daily pain scores and standard
dysmenorrhea surveys. For the first 8 weeks (Baseline Phase), participants will self-report on dysmenorrhea
symptoms to establish baseline values. Then, participants will be randomized (1:1) to the active or sham
treatment and self-administer daily treatment at home for the duration of the 8-week Treatment Phase while also
providing self-reports on dysmenorrhea symptoms. In this single study, we will evaluate metrics of feasibility
(Specific Aim 1) and acceptability (Specific Aim 2). After demonstrating feasibility in Phase I, we will conduct a
long-term pivotal clinical trial in Phase II to support FDA clearance and enable commercialization after Phase II.

Grant Number: 1R43HD115425-01
NIH Institute/Center: NIH
Principal Investigator: Daniel Burnett